Background: Recent evidence suggests that delayed HBeAg seroconversion is associated with poorer outcome. We aim to determine the incidence of HBeAg-negative chronic hepatitis B (CHB) according to the age at which HBeAg seroconversion occurs. Methods: Chronic hepatitis B patients with natural HBeAg seroconversion and over 12 months follow-up after HBeAg-seroconversion, and without complications, were included. Patients were followed 3−6 monthly with liver biochemistry. HBV DNA and liver stiffness measurements by transient elastography were determined at the time of last follow-up. HBeAgnegative CHB was defined as a combination of ALT elevation above the upper limit of normal on more than one occasion for the entire duration of fo...
Quantitative HBsAg has been recognized to assist in the management of chronic hepatitis B virus (HBV...
Background. Hepatitis B e antigen (HBeAg) status and serum hepatitis B virus (HBV) DNA levels are ma...
Recently, controversies have arisen about whether hepatitis B e antigen (HBeAg) seroconversion can r...
Hepatitis B e antigen (HBeAg)-negative hepatitis is a clinical indicator of poor outcome for chronic...
44th Annual Meeting of the European Association for the Study of the Liver Copenhagen, Denmar
Hepatitis B surface antigen (HBsAg) seroclearance is a rare event that occurs in 0.1% to 2% of patie...
In chronic hepatitis B virus (HBV) infection acquired during adulthood, which is the type mostly see...
This study was performed to determine the factors for predicting the occurrence of acute exacerbatio...
Background & Aims: Our aims were to study the virologic, histologic, and clinical outcome in chronic...
Background/Aims: The long-term virologic and biochemical changes in patients with HBeAg negative HBV...
The natural history of chronic hepatitis B is dependent on the age of acquiring the hepatitis B infe...
BACKGROUND: The role of HBsAg levels in predicting subsequent flares in chronic hepatitis B patients...
The aims of this study were to compare chronic hepatitis B (CHB) patients with genotypes B and C for...
Background and aim: Distinguishing inactive hepatitis B surface antigen (HBsAg) carriers from hepati...
BACKGROUND & AIMS: The role of quantitative hepatitis B surface antigen (HBsAg) after hepatitis B e-...
Quantitative HBsAg has been recognized to assist in the management of chronic hepatitis B virus (HBV...
Background. Hepatitis B e antigen (HBeAg) status and serum hepatitis B virus (HBV) DNA levels are ma...
Recently, controversies have arisen about whether hepatitis B e antigen (HBeAg) seroconversion can r...
Hepatitis B e antigen (HBeAg)-negative hepatitis is a clinical indicator of poor outcome for chronic...
44th Annual Meeting of the European Association for the Study of the Liver Copenhagen, Denmar
Hepatitis B surface antigen (HBsAg) seroclearance is a rare event that occurs in 0.1% to 2% of patie...
In chronic hepatitis B virus (HBV) infection acquired during adulthood, which is the type mostly see...
This study was performed to determine the factors for predicting the occurrence of acute exacerbatio...
Background & Aims: Our aims were to study the virologic, histologic, and clinical outcome in chronic...
Background/Aims: The long-term virologic and biochemical changes in patients with HBeAg negative HBV...
The natural history of chronic hepatitis B is dependent on the age of acquiring the hepatitis B infe...
BACKGROUND: The role of HBsAg levels in predicting subsequent flares in chronic hepatitis B patients...
The aims of this study were to compare chronic hepatitis B (CHB) patients with genotypes B and C for...
Background and aim: Distinguishing inactive hepatitis B surface antigen (HBsAg) carriers from hepati...
BACKGROUND & AIMS: The role of quantitative hepatitis B surface antigen (HBsAg) after hepatitis B e-...
Quantitative HBsAg has been recognized to assist in the management of chronic hepatitis B virus (HBV...
Background. Hepatitis B e antigen (HBeAg) status and serum hepatitis B virus (HBV) DNA levels are ma...
Recently, controversies have arisen about whether hepatitis B e antigen (HBeAg) seroconversion can r...